denkapparat Operations GmbH Takes Position in Hologic, Inc. (NASDAQ:HOLX)

denkapparat Operations GmbH purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 5,908 shares of the medical equipment provider's stock, valued at approximately $426,000.

Other large investors have also added to or reduced their stakes in the company. General Partner Inc. bought a new stake in Hologic in the fourth quarter worth $26,000. Groupama Asset Managment boosted its stake in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC boosted its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Institutional investors own 94.73% of the company's stock.

Hologic Stock Down 0.3 %

Shares of NASDAQ HOLX traded down $0.18 during mid-day trading on Tuesday, reaching $61.60. 514,566 shares of the company were exchanged, compared to its average volume of 1,805,534. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67. The firm has a 50-day moving average of $65.08 and a 200 day moving average of $73.11. The stock has a market cap of $13.82 billion, a price-to-earnings ratio of 19.43, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Remove Ads

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Morgan Stanley cut their target price on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They set a "peer perform" rating for the company. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Stephens reiterated an "overweight" rating and set a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Finally, Needham & Company LLC downgraded shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Hologic presently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.